The FDA responded with a complete response letter (CRL) to the resubmitted biologics license application (BLA) for RP1 (vusolimogene oderparepvec), an oncolytic virus therapy, in combination with ...
As people grow older, they become more vulnerable to illnesses such as the flu and COVID-19. Many families notice that what ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results